Inhibrx Biosciences, Inc. (INBX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol INBX
- Company Inhibrx Biosciences, Inc.
- Price $57.29
- Changes Percentage 102.01
- Change 28.93
- Day Low $46.02
- Day High $60.2
- Year High $60.2
- Year Low $10.81
- Market Cap $829,846,567
- Price Avg 50 EMA (D) $30.57
- Price Avg 200 EMA (D) $18.87
- Exchange NASDAQ
- Volume 6,033,096
- Average Volume 244,617
- Open $49.13
- Previous Close $28.36
- EPS -16.57
- PE -3.46
- Earnings Announcement 2025-11-14 20:00:00
- Shares Outstanding $14,485,016
Company brief: INHIBRX BIOSCIENCES, INC. (INBX )
- Healthcare
- Biotechnology
- Mr. Mark Paul Lappe
- https://inhibrx.com
- US
- N/A
- 08-19-2020
- US45720L1070
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
INBX Corporation News
Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing
seekingalpha.com -- Inhibrx Biosciences, Inc. delivered strong phase 2 results for ozekibart (INBRX-109) in advanced chondrosarcoma, doubling progression-free survival over placebo. INBX plans to file a Biologics License...
Inhibrx shares surge after bone cancer drug slows disease progression in trial
reuters.com -- Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer in a mid-stage trial, sending its shares surging over 70% in extended tradin...
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
prnewswire.com -- Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo Key se...